Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
How would you manage a patient with severe deforming seronegative RA who has failed or been intolerant to DMARDs, TNFi, abatacept, Jak inhibitors, IL-6 and IL-1 agents in addition to Rituxan and moderate dose prednisone?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Would you switch to a TNF-I if patient developed squamous cell skin cancer on Orencia after failure of MTX for seropositive RA?
